Further, CD8 ImmunoPET assessment of long-term immuno-surveillance in the context of recurrence, via GSC005 rechallenging, could further elucidate on positive immunological kinetics of immunotherapy response as past studies have shown strong immunological effects after rechallenging following virotherapy-induced tumor regression 14, 66. The gene discussed is CD8A; the disease is neoplasm.